Anacor Pharmaceuticals Inc. (ANAC) is scheduled to report top-line results from its phase III pivotal studies of Crisaborole Topical Ointment 2% for the potential treatment of mild-to-moderate atopic dermatitis in children and adults tomorrow.
Forex – financial instrument.Forex news
Anacor Pharmaceuticals Inc. (ANAC) is scheduled to report top-line results from its phase III pivotal studies of Crisaborole Topical Ointment 2% for the potential treatment of mild-to-moderate atopic dermatitis in children and adults tomorrow.